Genentech Plans Lucentis Launch Within 72 Hours Of Approval
This article was originally published in The Pink Sheet Daily
Genentech intends for its pending neovascular wet age-related macular degeneration product Lucentis (ranibizumab) to be available within three days of its approval
You may also be interested in...
The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles